Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? After all, consider the alternatives. Meanwhile, there is much to be done — meetings, deadlines, phone calls, bracing for the future. So please join us as we grab a cup of stimulation and dig in for another busy day. If you need a break, by the way, you can vote for the best biopharma CEO of the year (a separate list will appear shortly for the worst CEO, so sit tight). Meanwhile, here are some tidbits to help you get going. Have a splendid day and, of course, do keep in touch …

The House approved a proposal cracking down on the tactics drug makers use to charge Medicaid, The Hill writes. The bipartisan bill comes after the Department of Health and Human Services last year accused Mylan (MYL), which sells EpiPen, of overcharging Medicaid by as much as $1.27 billion over 10 years by misclassifying the drug as a generic. The bill would give HHS new authority to reclassify a drug and recoup rebates when a manufacturer deliberately misclassifies a drug in order to pay lower rebates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy